1. At a Glance – The Silent Antibiotic Factory Nobody Is Talking About
There’s something oddly suspicious about a company that sells life-saving antibiotics… but struggles to cure its own margins.
Welcome to Anuh Pharma Ltd — a company that quietly produces erythromycin (yes, the thing doctors prescribe when your throat feels like sandpaper), exports to 57+ countries, has ZERO debt, and still trades like it forgot to take its own medicine.
Let’s start with the paradox:
- Revenue growing nicely
- Capacity expanding aggressively
- Global approvals rolling in
- Debt almost nonexistent
And yet…
- Profit growth (TTM): -16.8%
- Margins swinging like a Mumbai local train handle
- Commoditized product portfolio (translation: price wars galore)
So what’s going on here?
This is a company that is:
- The largest producer of pyrazinamide globally
- Among top players in erythromycin salts
- Sitting on ₹83+ crore cash with minimal debt
And still struggling to command premium valuation.
It’s like being the biggest samosa seller in India… but competing with 200 street vendors selling the same thing cheaper.
Now the real question:
👉 Is this a hidden export machine quietly compounding?
👉 Or just another API company stuck in a price war with no moat?
Let’s investigate.
2. Introduction – Pharma Hero or Commodity Villain?
Anuh Pharma is part of the SK Group — not flashy, not headline-grabbing, not on CNBC every week.
Just quietly manufacturing bulk drugs since 1989.
Think of it as the backend of pharma — the ingredient supplier.
No marketing gimmicks. No brand recall.
Just molecules.
And not just any molecules:
- Anti-TB drugs
- Anti-bacterial APIs
- Anti-malarial ingredients
- Corticosteroids
Basically, if there’s a disease… Anuh probably makes something to fight it.
But here’s the twist:
👉 These are mature molecules
Which means:
- Everyone makes them
- Pricing power = weak
- Margins = volatile
Even ICRA politely says:
“Product profile of mature and commoditised molecules exposes margins to price-based competition.”
Translation:
“Boss, anyone can make this stuff… good luck keeping profits stable.”
And yet…
- Export presence across Europe, Africa, Asia
- Strong regulatory approvals (EDQM, WHO GMP)
- Continuous product additions
So why is the market not excited?
Because this business is like:
👉 Running on a treadmill — always moving, but rarely accelerating profits.
3. Business Model – WTF Do They Even Do?
Let’s simplify this.
Anuh Pharma = API manufacturer
They don’t sell medicines to you.
They sell ingredients to pharma companies who then sell finished medicines.
So basically:
You → Doctor → Medicine → Pharma Company → Anuh Pharma
They are 3 steps behind the spotlight.
Revenue Mix (9M FY24)
- Erythromycin: ~29%
- Sulphadoxine: ~17%
- Corticosteroids: ~17%
- Others spread across APIs
